Anti-PD-1 antibodies for treatment of lung cancer
The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.
1. A method of treating non-small cell lung cancer or increasing the survival of a patient with non-small cell lung cancer, comprising:
(a) selecting a patient with non-small cell lung cancer, wherein tumor tissue in the patient expresses programmed death ligand 1 (PD-L1) in ≥50% of tumor cells; and
(b) administering one or more doses of a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to programmed death 1 (PD-1) to the patient, thereby treating non-small cell lung cancer in the patient;
wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) of a heavy chain variable region (HCVR) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 3; HCDR2 comprises the amino acid sequence of SEQ ID NO: 4; HCDR3 comprises the amino acid sequence of SEQ ID NO: 5; LCDR1 comprises the amino acid sequence of SEQ ID NO: 6; LCDR2 comprises the amino acid sequence of SEQ ID NO: 7; and LCDR3 comprises the amino acid sequence of SEQ ID NO: 8.
2. The method of claim 1 , wherein the patient has not been previously treated with a systemic treatment for lung cancer.
3. The method of claim 1 , wherein the patient has been previously treated with anti-tumor therapy.
4. The method of claim 3 , wherein the anti-tumor therapy comprises platinum-based chemotherapy.
5. The method of claim 1 , wherein the non-small cell lung cancer is locally advanced and the patient is not a candidate for definitive chemoradiation, or the non-small cell lung cancer is metastatic.
6. The method of claim 1 , wherein the patient has advanced or recurrent non-small cell lung cancer.
7. The method of claim 1 , wherein the patient has squamous or non-squamous stage III or stage IV non-small cell lung cancer.
8. The method of claim 1 , wherein each dose of the antibody or antigen-binding fragment thereof is administered once a week, once every 2 weeks, once every 3 weeks, or once every 4 weeks.
9. The method of claim 1 , wherein each dose comprises 20 1500 mg of the antibody or antigen-binding fragment thereof.
10. The method of claim 1 , wherein each dose comprises 200, 250, 300, 350, 450, 600, 750, 800, 1000 or 1050 mg of the antibody or antigen-binding fragment thereof.
11. The method of claim 1 , wherein each dose comprises 350 mg of the antibody or antigen-binding fragment thereof and is administered every 3 weeks.
12. The method of claim 1 , wherein each dose of the antibody or antigen-binding fragment thereof comprises 0.1 10 mg/kg of the patient's body weight.
13. The method of claim 12 , wherein each dose of the antibody or antigen-binding fragment thereof comprises 1, 3, 4, 5, 6 or 10 mg/kg of the patient's body weight.
14. The method of claim 13 , wherein each dose is administered once a week, once every 2 weeks, once every 3 weeks, or once every 4 weeks.
15. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is administered as an intravenous infusion to the patient.
16. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is administered in combination with a second therapeutic agent or regimen selected from the group consisting of chemotherapy, an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, radiation, surgery, an anti-lymphocyte activation gene 3 (LAG-3) antibody, an anti-PD-L1 antibody, cyclophosphamide, a vaccine, an anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, a vascular endothelial growth factor (VEGF)-inhibiting fusion protein, an anti-VEGF antibody, sunitinib, sorafenib, pazopanib, an antibody to a tumor-specific antigen, granulocyte-macrophage colony-stimulating factor, a cytotoxin, a cytokine, a T-cell therapy, an anti-inflammatory drug, and a dietary supplement.
17. The method of claim 16 , wherein the antibody or antigen-binding fragment thereof is administered in combination with platinum-based chemotherapy.
18. The method of claim 16 , wherein the antibody or antigen-binding fragment thereof is administered in combination with an anti-CTLA-4 antibody.
19. The method of claim 1 , wherein the administration of at least one dose of the antibody or antigen-binding fragment thereof results in increasing the progression-free survival (PFS) or overall survival (OS) of the patient as compared to a patient who has been administered platinum-based chemotherapy as monotherapy.
20. The method of claim 19 , wherein the PFS is increased by at least one month as compared to a patient administered with platinum-based chemotherapy.
21. The method of claim 19 , wherein the OS is increased by at least one month as compared to a patient administered with platinum-based chemotherapy.
22. The method of claim 1 , wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 1 and the LCVR comprises the amino acid sequence of SEQ ID NO: 2.
23. The method of claim 1 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
24. The method of claim 1 , wherein the antibody is cemiplimab.
25. The method of claim 1 , wherein the patient has not tested positive for epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations, and/or ROS1 fusions.
26. A method of treating non-small cell lung cancer or increasing the survival of a patient with non-small cell lung cancer, comprising:
(a) selecting a patient with non-small cell lung cancer, wherein: (i) tumor tissue in the patient expresses programmed death ligand 1 (PD-L1) in >50% of tumor cells; (ii) the patient has not tested positive for epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations, and/or ROS1 fusions; (iii) the patient is not a candidate for definitive chemoradiation, or the non-small cell lung cancer is metastatic; and (iv) the patient has not been previously treated with a systemic treatment for non-small cell lung cancer; and
(b) administering to the patient an antibody that binds specifically to programmed death 1 (PD-1), thereby treating non-small cell lung cancer in the patient;
wherein the antibody comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) of a heavy chain variable region (HCVR) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 3; HCDR2 comprises the amino acid sequence of SEQ ID NO: 4; HCDR3 comprises the amino acid sequence of SEQ ID NO: 5; LCDR1 comprises the amino acid sequence of SEQ ID NO: 6; LCDR2 comprises the amino acid sequence of SEQ ID NO: 7; and LCDR3 comprises the amino acid sequence of SEQ ID NO: 8; and
the antibody is administered intravenously every three weeks at a dose of 350 mg.
27. The method of claim 26 , wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 1 and the LCVR comprises the amino acid sequence of SEQ ID NO: 2.
28. The method of claim 26 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
29. The method of claim 26 , wherein the antibody is cemiplimab.